Martin Šimkovič

Fakultní Nemocnice Hradec Králové

Czech Republic

Research Interests

Explore related searches

Professors in Immunology

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (14)

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Collaborators (9)

Peter Hillmen

UNITED KINGDOM

View details

Filip Vrbacký

University Hospital Hradec Králové

CZECH REPUBLIC

View details

Lukáš Smolej

CZECH REPUBLIC

View details

Constantine S. Tam

AUSTRALIA

View details

Jeffrey J. Pu

University of Arizona

UNITED STATES

View details

Tadeusz Robak

Professor

Medical University of Lodz

POLAND

View details

Frederick Lansigan

Dartmouth-Hitchcock Medical Center

UNITED STATES

View details

Martin Špaček

General University Hospital in Prague

CZECH REPUBLIC

View details

Paul M. Barr

University of Rochester

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Martin Šimkovič

Research Interests

Explore related searches

Contact this professor

Articles (14)

Complex evaluation of serum immunoglobulin levels in patients with chronic lymphocytic leukemia: Significant increase in IgA after first‐line chemoimmunotherapy

Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL

Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL

Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study

COVID-19 in patients with chronic lymphocytic leukemia: a multicenter analysis by the Czech CLL study group

COVID-19 in patients with chronic lymphocytic leukemia: a multicenter analysis by the Czech CLL study group

A comprehensive assessment of lymphocyte subsets, their prognostic significance, and changes after first‐line therapy administration in patients with chronic lymphocytic leukemia

A comprehensive assessment of lymphocyte subsets, their prognostic significance, and changes after first-line therapy administration in patients with chronic lymphocytic leukemia

Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial

Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR)

Extended Follow-up of ALPINE Randomized Phase 3 Study Confirms Sustained Superior Progression-Free Survival of Zanubrutinib Versus Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL)

Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen

Acalabrutinib Versus Investigator's Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results

CLL-115 First Interim Analysis of ALPINE Study: Results of a Phase 3 Randomized Study of Zanubrutinib vs Ibrutinib in Patients With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Collaborators (9)

Peter Hillmen

Filip Vrbacký

Lukáš Smolej

Constantine S. Tam

Jeffrey J. Pu

Tadeusz Robak

Frederick Lansigan

Martin Špaček

Paul M. Barr

Make your next move.